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ABsTrAcT
Background: We have previously shown that MYCN knockdown causes a G1 arrest in 
MYCN amplified (MNA), p53 wild type (wt) and p53 mutant MNA neuroblastoma cell 
lines, with increases in p21WAF1 and hypo RB in p53 wt cell lines.1
Hypothesis: MYCN acts by inhibiting p21WAF1, and also by p21WAF1 independent 
mechanisms to override the G1 checkpoint in exponentially growing cells.
Methods: Genes potentially regulated by MYCN were identified using gene expression 
microarrays in p53 wt MNA IMR‑32 and p53 mutant MNA SKNBE(2c) neuroblastoma 
cell lines treated with MYCN or scrambled siRNA. Results were validated using qRT‑PCR 
and confirmed using the regulatable MYCN expression system (SHEP Tet21N).
Results: MYCN knockdown altered the expression of several cell cycle related genes. 
SKP2 was down regulated in both cell lines, and up regulated in MYCN+ Tet21N cells. 
Expression of the WNT antagonist DKK3 increased in both cell lines and decreased in 
MYCN+ Tet21N cells. Expression of CDKN1C (p57cip2) and TP53INP1 also increased 
after MYCN knockdown.
Conclusions: MYCN may override the G1 checkpoint through down‑regulation of SKP2 
and TP53INP1 resulting in reduced p21WAF1 expression in p53 wt cell lines, and in 
addition may act through the WNT signaling pathway in a p53 independent manner.
InTroDucTIon
Neuroblastoma is a childhood cancer derived from cells of the migrating neural crest. 
A number of genetic aberrations occur in aggressive neuroblastoma including MYCN 
amplification (MNA), chromosome 1p deletion and unbalanced gain of chromosome 17q. 
MNA occurs in ~20–25% of neuroblastoma cases and there is a strong correlation between 
MNA and poor prognosis.2 MYCN, one of the MYC family of oncogenes structurally 
related to MYCC and MYCL, maps to chromosome 2p24. Ectopically regulated expression 
of MYCN has been shown to have similar effects transcriptionally and on the cell cycle as 
MYCC: increasing the expression of a-prothymosin and ornithine decarboxylase (ODC), 
and increasing the proliferation rate in the presence of growth factors.3
p53 plays a key role in maintaining genetic integrity in response to DNA damage. 
Activated p53 increases the expression of target genes including CDKN1A (p21WAF1) to 
elicit a G1 arrest, or BAX to activate apoptosis. p53 also up-regulates the expression of 
MDM2, a protein responsible for targeting p53 for degradation. This forms an auto regu-
latory loop to tightly regulate p53 levels in the cell.4 p53 mutations in neuroblastoma are 
rare at diagnosis, however they do develop in response to cytotoxic therapy.5 Other aber-
rations in the p53 pathway have also been reported in cell lines established from relapsed 
tumors, such as p14ARF deletion and methylation, and MDM2 amplification.6
After DNA damage MNA wild type neuroblastoma cell lines have lower levels of 
p21WAF1 induction than non-MNA ones, and fail to undergo a G1 arrest despite having 
wt p53.1,7,8 p21WAF1 causes a G1 arrest by inhibiting the activity of cyclin E/cdk2 
complexes, preventing the phosphorylation of RB and release of the E2F transcription 
factor.9 p21WAF1 levels are regulated at the transcriptional level by epigenetic silencing and 
mRNA stability. At the protein level p21WAF1 is regulated by ubiquitin dependent and 
independent protein degradation pathways.10 MYCC has been shown to repress p21WAF1 
expression at the transcriptional level through direct binding to the CDKN1A promoter 
after recruitment by Miz-1,11 or by the sequestration of the SP1/SP3 CDKN1A transcrip-
tional activator proteins.12
We recently reported ectopic expression of MYCN in a non-MNA neuroblastoma cell 
line did not affect p21WAF1 induction or the G1 arrest in response to DNA damage, and 
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MYCN knockdown in MNA cell lines did not restore a G1 arrest 
after DNA damage, indicating that high levels of MYCN alone 
are not responsible for the failure to G1 arrest after DNA damage.
1 
Knockdown of MYCN expression by RNAi in 3 p53 wt MNA cell 
lines caused an accumulation of cells in G1 alongside increases in 
p21WAF1 and hypophosphorylated (hypo) RB, and MYCN knock-
down in a p53 mutant cell line caused a G1 arrest with no increase in 
p21WAF1 or hypo RB.1 This suggests that MYCN acts through p53 
to decrease levels of p21WAF1, and via a p53 independent mecha-
nism to affect the G1 checkpoint. In this study we investigated how 
MYCN acts on the G1 checkpoint under normal growth conditions, 
by identifying potential downstream MYCN targets using MYCN 
siRNA in MNA neuroblastoma cell lines and gene expression micro-
array. In addition we investigated the effect of MYCN knockdown 
on levels of p21WAF1 after irradiation.
mATErIALs AnD mEThoDs
Cell lines. The p53 wt IMR-3213 and p53 mutant SKNBE(2c)7 
cell lines were used for gene expression microarray experiments. 
GIMEN, NB69, LAN-6, NBL-S, PER108, SMSKCNR, NBLW, 
CHLA-136 and NGP cells were used as described previously.1 All cell 
lines were grown in RPMI 1640 (Gibco, Paisley, UK) supplemented 
with 10% Fetal Calf Serum (FCS) (Gibco). Cells were grown at 
37˚C, in a 5% CO2 humidified incubator.
DNA damage using g‑irradiation. Cells were plated in 28 cm2 
tissue culture dishes (Nunc, Naperville, IL) at 5 x 105 cells per plate 
and irradiated when ~ 70% confluent with 4Gy 310kV X-rays from a 
RS320 irradiation system (Gulmay Medical, Surrey, UK). Cells were 
harvested 2, 6 and 24 hours post irradiation for Western blotting. 
Experiments were carried out at least twice.
Western blotting. Whole cell extracts were prepared, and 30mg 
protein/sample separated by gel electrophoresis, and Western blot-
ting performed using methods described previously.8 Densitometry 
was performed using a Fuji-Las camera and the AIDA image analyser 
programme (Raytek, Sheffield, UK) used to quantify band intensi-
ties. Primary antibodies used were mouse monoclonal p53 DO7 at 
1:1000 (Novocastra, Newcastle, UK), MDM2 at 1:100, p21WAF1 
at 1:100 (Calbiochem, Cambridge, MA), hypophosphorylated reti-
noblastoma protein (hypo RB) at 1:100 (BD iosciences, Oxford 
UK), rabbit polyclonal SKP2 antibody (Sc7164) at 1:100 (Santa 
Cruz Biotechnology, Santa Cruz, CA) and mouse monoclonal 
MYCN 100 antibody at 1:100 dilution (gift from N. Igekaki). 
b-actin rabbit polyclonal antibody was used as a protein loading and 
transfer control at 1:1000 (Sigma, St. Louis, MO). The secondary 
goat anti-mouse and goat anti-rabbit antibodies were used at 1:1000 
(DAKO, Glostrup, Denmark).
MYCN knockdown using siRNA. MYCN siRNA was performed 
using the methods previously described.1 40nM of MYCN or scram-
bled (SCR) siRNA was transfected into IMR-32 cells, and 25nM 
siRNA was transfected into p53 mutant SKNBE(2c) cells. A time 
course was carried out and maximal reduction in MYCN protein 
expression was observed in both cell lines 14 hours after transfection 
of MYCN siRNA. Cells were harvested 16 hours post transfection to 
look for early changes in gene expression and 48 hours later to look 
for later changes. Experiments were carried out in duplicate.
MYCN up regulation using the SHEP Tet21N system. The 
SHEP Tet21N cell line3 was grown in RPMI 1640 supplemented 
with 10% tetracycline-free FCS (Clontech, Mountain View, CA), 
G418 and hygromycin (Promega, Southampton, UK). SHEP 
Tet21N cells express MYCN in the absence of tetracycline. To switch 
off MYCN expression, 10mg/ml tetracycline (Sigma) was added to 
growth media at least 24 hours prior to experiments.
Gene expression microarray. Cells were harvested 16 and 48 
hours post siRNA transfection for microarray analysis. Total RNA 
was extracted using the RNeasy Midi kit (Qiagen, Ontario, Canada) 
and RNA integrity measured using a Bioanalyser (Agilent, Palo Alto, 
CA). Total cDNA was synthesized using a T7-Oligo dT Promoter 
Primer Kit (Affymetrix, Santa Clara, CA). In vitro transcription using 
biotinylated dUTP and dCTP was carried out using the Bioarray 
high yield transcript labelling kit (Enzo Diagnostics, Farmingdale, 
NY). Resulting cRNA was hybridized to a test array to assess the 
quality of the labelled nucleic acid before hybridising to U133 plus 
2.0 Affymetrix arrays. Arrays were scanned using Microarray suite 
5.0, and data was exported as CEL files. The cRNA synthesis, micro-
array hybridization and signal scanning steps were undertaken at the 
Cancer Research UK facility (Paterson Institute, Manchester, UK). 
Gene assignments to probe sets and candidate genes were analysed 
using Genespring GX version 7.1 (Agilent). Microarrays were carried 
out in duplicate for each condition (biological replicates). The array 
data for one of the replicates of the 48 h SCR treated SKNBE(2c) 
cells was omitted from the analysis because hierarchical clustering 
and principal components analysis on all of the genes in the array 
found that this replicate did not cluster with the other SKNBE(2c) 
arrays, suggesting unreliable data.
A comparison of differentially expressed genes was carried out 
for both cell lines at each time point. The cell cycle, cell growth 
and signal transduction gene lists (GO:0007049, GO:0016049 and 
GO:0030154) from the Gene Ontology database were compared 
between MYCN and SCR siRNA treated cell lines at 16 and 48 
hours post siRNA transfection. There were fewer cell cycle related 
genes differentially regulated at 16 hours, so all genes with a ≥2 fold 
change in expression level were included. A larger number of cell 
cycle genes were differentially expressed at 48 hours and only genes 
with a ≥3 fold change were included.
Validation of gene expression microarray results using quan‑
titative reverse transcriptase PCR. For selected genes of interest, 
microarray results were validated using quantitative reverse transcrip-
tase PCR (qRT-PCR). RNA extraction, reverse transcriptase PCR and 
qPCR was carried out as described previously.6 Primers and probes 
for Dickkopf 3 (DKK3), p53 inducible protein 1 (TP53INP1), 
S-phase associated kinase (SKP2), cyclin dependent kinase inhibitor 
1C (CDKN1C), ODC and the control b-Actin were Taqman assays 
(Applied Biosystems, Foster City, CA). Each sample was run in trip-
licate on a 384 well plate using an ABI prism 7900 detection kit and 
results were analysed using SDS 2.2 (both from Applied Biosystems). 
Each experiment was repeated three times.
rEsuLTs
MYCN RNA and protein levels after MYCN knockdown. The 
amount of MYCN knockdown achieved in IMR-32 and SKNBE(2c) 
cells is shown in Figure 1A and B. MYCN protein knockdown 
was 36–71% in IMR-32 cells and 30–62% in SKNBE(2c) cells. 
The extent of MYCN knockdown in MYCN siRNA treated cells 
compared to SCR controls was not as high at the transcript level in 
both IMR-32 and SKNBE(2c) cells (Fig. 1A and B). 58.5% (mean) 
knockdown was observed in IMR-32 cells at 16 hours recovering 
to normal transcript levels at 48 hours post transfection. 49.5% 
(mean) knockdown was observed in the SKNBE(2c) cells at 16 hours 
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recovering to 22.5% knockdown at 48 hours. Protein knockdown 
remained unchanged between 16 and 48 hours post transfection in 
both cell lines (Fig. 1B).
Cell cycle related gene expression microarray results after MYCN 
siRNA knockdown. Venn diagrams showing cell cycle related genes 
differentially expressed at 16 and 48 hours after transfection in 
IMR-32 and SKNBE(2c) cells are shown in (Fig. 1C). More genes 
were up-regulated than down regulated after MYCN knockdown, 
suggesting that MYCN represses transcription of numerous cell 
cycle related genes. In IMR-32 cells MYCN mRNA knockdown 
was detected in both cell lines 16 hours after transfection (Fig. 2A 
and B and Table 1), but not at 48 hours, confirming the qRT-PCR 
results (Fig. 1A).
Some previously reported MYCN target genes e.g., ODC and 
a-prothymyosin did not change. qRT-PCR was carried out for 
ODC, and confirmed that the fold decrease at both time points for 
both cell lines was <2 fold (data not shown). Other previously 
identified MYCN targets were differentially regulated in MYCN 
and SCR treated IMR-32 cells: MYCC (Fig. 2A) and CDC42 (Fig. 
2C). Cross regulation of MYCC by MYCN has previously been 
described.14,15 CDC42, also repressed by MYCN,16 was up-regulated 
in MYCN siRNA treated IMR-32 cells at 48 hours. CDC42 however 
was not up regulated in p53 mutant SKNBE(2c) cells, suggesting 
that p53 may be involved in the regulation of CDC42 by MYCN 
(Fig. 2C).
Early changes in cell cycle related gene expression after MYCN 
knockdown. Genes differentially expressed in IMR-32 cells alone 
at 16 hours are shown in Figure 2A. A greater number of cell 
cycle related genes were differentially expressed in IMR-32 cells at 
16 hours (60 probes, 46 genes) compared with SKNBE(2c) (24 
probes, 23 genes) (Fig. 2B). This suggests that MYCN might 
modulate many genes in a p53 dependent manner. In IMR-32 cells 
two cyclins: cyclin A1 (CCNA1) and cyclin G2 (CCNG2) were 
upregulated alongside the cyclin dependent kinase inhibitor p57kip2 
Figure 1. (A) Levels of MYCN transcripts using qRT‑PCR 16 and 48 hours after transfection with MYCN or SCR siRNA alongside untreated controls. (B) Levels 
of MYCN protein after knockdown in IMR‑32 and SKNBE(2c) cells. (C) Venn diagram showing cell cycle related genes differentially regulated 16 hours and 
48 hours after transfection with MYCN siRNA in IMR‑32 and SKNBE(2c) cells.
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Figure 2. Cell cycle related genes >2 fold differentially regulated in (A) IMR‑32 cells and (B) SKNBE(2c) 16 hours after MYCN knockdown. Cell cycle related 
genes >3 fold differentially regulated in (C) IMR‑32 and (D) SKNBE(2c) cells 48 hours after MYCN knockdown.
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(CDKN1C) gene (Fig. 2A). Changes in expression of six genes were 
common to both IMR-32 and SKNBE(2c) cells: DKK3, EDG7, 
LEPR, MYCN, SKP2 and SKIL. The up regulated genes included 
DKK3, an antagonist of WNT signaling17 and SKIL (Ski-like onco-
gene), which represses Smad transcription factors involved in TGFb 
signaling.18 SKP2, a component of the Skp1-Cullin-F-box-skp2.
Roc1 ubiquitin ligase complex (SCFskp2.Roc1)19 was down regulated 
(Fig. 1C, 2A, 2B and Table 1).
Late changes in cell cycle related gene expression after MYCN 
knockdown. Cell cycle related genes differentially expressed 48 hours 
after MYCN knockdown compared with SCR siRNA controls are 
shown in Figure 2C and D. Forty-six genes and 53 probes were 
differentially regulated in the IMR-32 cells (Fig. 2C). All genes 
identified in IMR-32 cells had increased expression after MYCN 
knockdown. The gene with the greatest fold increase in IMR-32 cells 
was c‑hluPGFS (AKR1C3) a member of the aldoketose reductase 
family. AKR1C3 had increased expression in IMR-32 cells alone 
(Fig. 2C). Two genes involved in transforming growth factor (TGF) 
signaling were up-regulated: TGFb-II and CDKN1C (Fig. 2C). The 
expression of a number of tumor suppressor genes was increased in 
IMR-32 cells when MYCN was knocked down: NDRG1, ARHI, 
LGI1 and TP53INP1 (Fig. 2C). Interestingly, low expression of 
ARHI, which is located at 1p31, was found to be associated with a 
poor outcome in neuroblastoma.20 ARHI is a maternally imprinted 
gene, and its loss of expression has also been implicated in both 
ovarian and breast cancer.21 Thirty-five genes (37 probes) were differ-
entially regulated in SKNBE(2c) cells, these include the up regulation 
of the mitotic progression protein NEK7 and the RET oncogene 
(Fig. 2D). Genes increased in expression in both cell lines at 48 hours 
included the WNT antagonist DKK3, CHRM1 (muscarinic receptor 
M1) and Testican‑1 (Table 1). The following genes were chosen for 
validation by qRT-PCR: DKK3, SKP2, CDKN1C and TP53INP1.
Validation of microarray results. Changes in expression of 
selected genes were validated in IMR-32 and SKNBE(2c) cells, 
and in MYCN+ and MYCN- SHEP Tet21N cells, to deter-
mine if increasing MYCN expression had the opposite effect to 
MYCN knockdown.
SKP2. Levels of SKP2 down regulation by qRT-PCR were 
smaller than by microarray. A ~2 fold reduction in SKP2 mRNA 
was observed in both cell lines 16 hours after transfection (Fig. 3A). 
Reduction in SKP2 expression in MYCN siRNA treated IMR-32 
cells was confirmed using Western blotting 48 hours post transfection 
(Fig. 3B), showing that SKP2 protein levels were low despite restora-
tion of transcript levels by this time. There was a two-fold increase in 
SKP2 transcripts in Tet21N MYCN+ cells compared to MYCN- cells 
(Fig. 3A). However, the level of SKP2 protein did not correlate with 
MYCN expression or MNA status across a panel of neuroblastoma 
Table 1 List of cell cycle related genes that are differentially regulated 16 and/or 48 hours after MYCN siRNA   
 treatment in both IMR‑32 and SKNBE(2c) cells*
gene Description  mean Fold change 
  16h Imr‑32 48h Imr‑32 16h sKnBE2c 48h sKnBE2c
CHRM1 Brn25 Homo sapiens cDNA clone 1.3      ± 0.8 3.3  ± 1.4 1.0  ± 0.3 3.6  ± 0.2
DKK3 Dickkopf (X. laevis) homolog 3 2.2 ± 1.0 4.5 ± 0.8 2.0 ± 0.1 3.8 ± 0.5
EDG7 Lysophosphatidic acid receptor 0.3 ± 0.004 0.4 ± 0.001 0.5 ± 0.001 1.4 ± 0.001
LEPR Leptin receptor 2.2 ± 0.001 1.9 ± 0.01 2.42 ± 0.01 0.9 ± 0.01
NMYC (1) v‑myc myelocytomatosis viral related oncogene 0.1 ± 0.1 0.4 ± 0.2 0.3 ± 0.2 1.3 ± 0.8
NMYC (2) v‑myc myelocytomatosis viral related oncogene 0.1 ± 0.1 0.5 ± 0.2 0.2 ± 0.1 0.8 ± 0.03
SKIL Ski‑like oncogene 2.2 ± 0.05 1.09 ± 0.02 2.16 ± 0.4 1.8 ± 0.001
SKP2 S‑phase kinase‑associated protein 2 (p45) 0.3 ± 0.2 0.5 ± 0.2 0.4 ± 0.4 1.2 ± 0.6
TIC1 Testican‑1                                                       1.0 ± 0.002       3.8 ± 0.1       1.0 ± 0.01        3.1 ± 2.7
*The fold differences relative to the SCR control are shown at 16 and 48 hours for both cell lines. Note: The genes in bold were validated using qRT-PCR.
Figure 3. Validation of (A) SKP2 transcript levels after MYCN knockdown 
in IMR‑32 and SKNBE(2c) cells. (B) SKP2 protein levels after MYCN knock‑
down. (C) Levels of SKP2 protein expression determined by WB in a panel 
of 13 neuroblastoma cell lines.
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cell lines (Fig. 3C). The non-MNA SKNRA, SJNB-1, LAN-6, 
SHSY5Y and the MNA PER-108 and IMR-32 cell lines all had high 
levels of SKP2 expression.
DKK3. qRT-PCR confirmed increased DKK3 expression 
48 hours after MYCN siRNA transfection with DKK3 mRNA levels 
3 fold higher in IMR32 cells compared with SCR treated controls 
and 2.5 fold higher in SKNBE(2c) cells than SCR controls. 
Conversely, DKK3 expression in MYCN+ Tet21N cells was ~2 fold 
less than MYCN- Tet21N cells (Fig. 4A).
TP53INP1. In IMR-32 cells, TP53INP1 mRNA expression 
increased 1.5 fold at 16 hours and ~7 fold 48 hours after MYCN 
siRNA transfection. Levels of TP53INP1 were lower in p53 mutant 
SKNBE(2c) cells, with ~2 fold increase in TP53INP1 observed in 
SKNBE(2c) cells by qRT-PCR. In contrast, TP53INP1 levels were 
~2 fold higher in MYCN+ Tet21N cells compared with MYCN- 
Tet21N cells (Fig. 4B).
p57cip/kip2. Levels of p57cip/kip2 mRNA increased ~6 fold in 
IMR-32 cells 48 hours after siRNA transfection, however there was 
no change in p53 mutant SKNBE(2c) cells confirming the microarray 
observations, or in Tet21N MYCN+ and MYCN- cells (Fig. 4C).
p21WAF1 protein levels after irradiation in MYCN siRNA treated 
IMR‑32 cells. The p53 response to DNA damage was examined after 
MYCN knockdown in IMR-32 cells (Fig. 4D). Levels of MDM2 
induction at 6 hours were 4 fold higher in MYCN compared to SCR 
siRNA treated IMR-32 cells and levels of p53, p21WAF1 and hypo RB 
were similar in MYCN and SCR siRNA treated cells after irradiation.
DIscussIon
Investigation of possible downstream targets of MYCN using 
MYCN knockdown to alter gene expression gives an insight into 
genes affected by high level MYCN expression that may not be 
identified by investigating ectopic MYCN expression in a non-MNA 
cell line alone. MYCC binds some of its downstream targets with a 
high affinity, and another group of genes with low affinity. MYCC 
binding at low affinity sites sharply increased with increasing levels 
of MYCC.22 The low affinity binding sites will probably be most 
affected by high levels of MYCN expression resulting from MNA. 
The current study has identified a number of genes involved in 
regulation of the G1 checkpoint that are differentially expressed after 
MYCN knockdown.
MYCN effects on p21WAF1 during normal growth conditions. 
We previously reported that MNA neuroblastoma cells treated with 
MYCN siRNA accumulated in the G1 phase of the cell cycle 48 
hours after transfection.1 In p53 wt cell lines this was accompanied 
by an increase in p21WAF1 protein expression and hypo RB, with no 
change in p53 levels. In p53 mutant SKNBE(2c) cells MYCN knock-
down increased the G1 population, without an increase in p21
WAF1 
or hypo RB.1 Data from the present study, suggests that increases 
in p21WAF1 levels in p53 wt IMR-32 cells after MYCN knockdown 
may be due to decreased SKP2 and increased TP53INP1 levels 
(Table 1, Figs. 3A  and 4B). SKP2 is part of the SCFskp2 complex 
(composed of: Rbx, Cul1, SKP1 and SKP2). Ubiquitination of 
Figure 4. Validation of transcript levels of cell cycle genes after MYCN knockdown in IMR‑32, SKNBE(2c) and Tet21N MYCN+ and MYCN‑ cells: (A) DKK3 
(B) TP53INP1 (C) CDKN1C/p57kip d) The p53 response to 4Gy g‑irradiation induced DNA damage after MYCN knockdown in IMR‑32 cells, compared 
to SCR siRNA treated cells.
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p21WAF1 by SCFskp2 requires the functional interaction of p21WAF1 
with cyclin E-CDK2 complex.23 Reduction of SKP2 after MYCN 
knockdown may decrease SCFskp2 mediated degradation of p21WAF1, 
allowing p21WAF1 to accumulate and induce a G1 arrest in p53 wt cells.
TP53INP1 has been reported to cause a G1 arrest and apoptosis.
24 
TP53INP1 regulates p53 and p73 transcriptional activity, and in 
particular has been found to increase p53-dependent p21WAF1 tran-
scription.25 The increase in p21WAF1 and MDM2 after irradiation in 
IMR-32 cells after MYCN knockdown may also be due to increases 
in TP53INP1 levels (Fig. 4D). It has previously been demonstrated 
that MDM2 is a downstream transcriptional target of MYCN,26,27 
but in this study we did not observe any change in MDM2 levels 
after MYCN knockdown at the RNA or protein level.
SKP2 levels were reduced in p53 mutant SKNBE(2c) cells after 
MYCN knockdown (Fig. 3A), however no increase in p21WAF1 levels 
were observed,1 p21WAF1/CDKN1C is a p53 induced gene.28 Levels 
of TP53INP1 did not increase in p53 mutant SKNBE(2c) cells 
which is possibly because TP53INP1 is induced after cellular stress 
by p53 mediated transcription.25 However, loss of p53 activity does 
not explain the result for the p53 wt MYCN+ Tet21N cells, where 
high MYCN expression increases levels of TP53INP1.
Other potential effects of MYCN on the cell cycle. We have found 
that MYCN acts on two pathways that converge on cyclin D/CDK4/6 
complexes at the G1 checkpoint, providing a potential mechanism by 
which MYCN acts independently of p21WAF1 
(Fig. 5). Components of the WNT signaling 
and transforming growth factorb (TGFb) 
pathways are affected by MYCN knockdown 
(Fig. 2 and Table 1). DKK3, a member 
of the Dickkopf family of secreted WNT 
antagonists, was upregulated 48 hours after 
MYCN knockdown in both cell lines. DKK3 
has been shown to modulate the activity 
and localization of b-catenin, a mediator 
of WNT signaling, targeting it to the cell 
membrane, reducing the amount of b-catenin 
in the nucleus so preventing its transcriptional 
activity.17 Stabilized b-catenin, the product of 
positive regulation of WNT signaling, tran-
scriptionally upregulates cyclin D,29 MYCC,30 
c-jun and fra-1,31 all of which affect the 
cell cycle. GSK-3b which is downstream of 
b-catenin in WNT signaling, also negatively 
regulates cyclin D via phosphorylation of Thr 
286, targeting cyclin D for degradation.32 The 
increase in DKK3 levels observed after MYCN 
knockdown may cause a G1 arrest through the 
negative regulation of b-catenin and cyclin 
D. This p53 independent mechanism may be 
responsible for the accumulation of cells in 
G1 after MYCN knockdown in p53 mutant 
SKNBE(2c) cells.1
Transforming growth factor b (TGFb) is 
a potent inhibitor of cell proliferation and 
induces differentiation and growth arrest in 
certain cell types. TGFb signaling pathway 
targets include bone morphogenic proteins, 
Smad transcription factors and activins.33 
Levels of TGFb2 and p57cip2 expression 
increased 48 hours after MYCN knockdown 
in p53wt IMR-32 cells. p57cip2, a cyclin dependent kinase (CDK) 
inhibitor that targets cyclin D-CDK4/6 complexes is the downstream 
transcriptional target of TGFb signaling which causes a G1 arrest.34 
Therefore, deregulated MYCN expression in MNA cell lines may 
repress TGFb signaling in order to prevent cyclin D inhibition by 
p57cip2. An increase in p57cip2 expression was not observed in the 
SKNBE(2c) cells. p57cip2/CDKN1C is a paternally imprinted/gene,35 
it is possible that the other allele may be methylated or lost in 
SKNBE(2c) and Tet21N cells, in which p57cip2 levels do not change 
after MYCN knockdown.
MYCN effects on p21WAF1 induction after DNA damage. 
Cyclin A1 (CCNA1), the only cyclin to be induced by g-irradiation36 
had increased expression sixteen hours after MYCN knockdown 
in IMR-32 cells (Fig. 2A). Cyclin A1 expression did not change 
in SKNBE(2c) cells, in line with cyclin A1 being a p53 inducible 
gene.37 Cyclin A1 binds to CDK2 and plays a role in meiosis in 
male germ cells. It also phosphorylates Ku70, a DNA repair protein 
responsible for repairing double strand breaks (DSB). Cyclin A1 is 
involved in non-homologous end joining after DNA damage. Cyclin 
A1-/- cells are DSB repair deficient and have increased radiosensi-
tivity.36 MYCN downregulation of cyclin A1 might partly explain 
our previous observations of MNA neuroblastoma cell lines under-
going apoptosis after irradiation in preference to a G1 arrest in which 
DNA damage would be repaired.1
Figure 5. Proposed mechanism of how MYCN might act via DKK3 and p57cip/kip2 to affect the G1 
checkpoint in MNA neuroblastoma cells. Phosphorylation (p+) and increased expression (e).
www.landesbioscience.com Cell Cycle 1255
©2
007
 LA
ND
ES 
BIO
SCI
EN
CE.
 DO
 NO
T D
IST
RIB
UT
E.
Cell Cycle Targets of MYCN
This study sought an explanation for the effects of MYCN knock-
down on the G1 checkpoint in proliferating cells. Our data suggest 
a possible mechanism by which MYCN might repress p21WAF1 
expression by increasing SKP2 and decreasing TP53INP1 expres-
sion. In addition MYCN may also act independently of p21WAF1 by 
decreasing levels of the WNT antagonist DKK3. This study has iden-
tified new pathways potentially regulated by MYCN which warrant 
further investigation and may provide novel therapeutic targets for 
MNA neuroblastoma.
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